Mutation and drug-specific intracellular accumulation of EGFR predict clinical responses to tyrosine kinase inhibitors

BACKGROUND: Clinical responses to EGFR tyrosine kinase inhibitors (TKIs) are restricted to tumors harboring specific activating mutations and even then, not all tyrosine kinase inhibitors provide clinical benefit. All TKIs however, effectively inhibit EGFR phosphorylation regardless of the mutation...

Descripción completa

Detalles Bibliográficos
Autores principales: de Wit, Maurice, Gao, Ya, Mercieca, Darlene, de Heer, Iris, Valkenburg, Bart, van Royen, Martin E., Aerts, Joachim, Sillevis Smitt, Peter, French, Pim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7276512/
https://www.ncbi.nlm.nih.gov/pubmed/32512509
http://dx.doi.org/10.1016/j.ebiom.2020.102796

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7276512/
https://www.ncbi.nlm.nih.gov/pubmed/32512509
http://dx.doi.org/10.1016/j.ebiom.2020.102796

Ejemplares similares